## Jaw-Ching Wu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2224687/publications.pdf

Version: 2024-02-01

50244 66879 7,136 152 46 78 citations h-index g-index papers 152 152 152 7925 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. Journal of the Chinese Medical Association, 2022, 85, 30-41.	0.6	7
2	Bi-directional gene activation and repression promote ASC differentiation and enhance bone healing in osteoporotic rats. Molecular Therapy, 2022, 30, 92-104.	3.7	5
3	Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. Cells, 2022, 11, 634.	1.8	8
4	Differential prognoses among male and female patients with hepatocellular carcinoma. Journal of the Chinese Medical Association, 2022, 85, 554-565.	0.6	11
5	Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection. Journal of the Chinese Medical Association, 2022, 85, 679-686.	0.6	5
6	Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. Scientific Reports, 2022, 12, 8343.	1.6	5
7	The role of albumin–bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 136-143.	0.6	8
8	Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development. Hepatology, 2021, 74, 641-655.	3 <b>.</b> 6	27
9	Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. Hepatology International, 2021, 15, 1421-1430.	1.9	15
10	The correlation between fatty liver disease and chronic kidney disease. Journal of the Formosan Medical Association, 2020, 119, 42-50.	0.8	16
11	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. Journal of the Formosan Medical Association, 2020, 119, 610-620.	0.8	13
12	Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2020, 32, 365-372.	0.8	2
13	A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Scientific Reports, 2020, 10, 17259.	1.6	7
14	Statin inhibits large hepatitis delta antigen-Smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion. Journal of Biomedical Science, 2020, 27, 65.	2.6	7
15	Reply to letter to the editor: Insights into chronic migraine pathophysiology – what measures of gray matter reveal. Cephalalgia, 2020, 40, 1138-1139.	1.8	1
16	Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. Scientific Reports, 2020, 10, 2006.	1.6	7
17	Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B. Journal of the Chinese Medical Association, 2020, 83, 125-133.	0.6	4
18	Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 238-238.	0.7	17

#	Article	IF	CITATIONS
19	High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. Cancers, 2019, 11, 1549.	1.7	12
20	Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study. Gastroenterology Research and Practice, 2019, 2019, 1-8.	0.7	11
21	Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association, 2019, 82, 2-10.	0.6	16
22	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology, 2019, 69, 1151-1164.	3.6	22
23	Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinomaÂwho does not require endoscopic screening for esophageal varices. Gastrointestinal Endoscopy, 2018, 88, 230-239.e2.	0.5	30
24	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2018, 117, 381-403.	0.8	92
25	Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2018, 30, 1368-1377.	0.8	7
26	Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelialâ $\in$ Mesenchymal Transition Regulators and Stemness Genes. Hepatology Communications, 2018, 2, 1392-1407.	2.0	25
27	The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer, 2018, 7, 335-358.	4.2	27
28	Synthetic switch-based baculovirus for transgene expression control and selective killing of hepatocellular carcinoma cells. Nucleic Acids Research, 2018, 46, e93-e93.	6.5	22
29	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Scientific Reports, 2017, 7, 42577.	1.6	25
30	Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study. American Journal of Gastroenterology, 2017, 112, 1084-1093.	0.2	52
31	The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. International Journal of Cancer, 2017, 141, 1307-1314.	2.3	70
32	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. Radiology, 2017, 285, 670-680.	3.6	88
33	Hepatocellular carcinomaâ€associated singleâ€nucleotide variants and deletions identified by the use of genomeâ€wide highâ€throughput analysis of hepatitis B virus. Journal of Pathology, 2017, 243, 176-192.	2.1	29
34	Expression of a hepatitis B virus preâ€ <scp>S2</scp> deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice. Journal of Pathology, 2017, 241, 463-474.	2.1	38
35	Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. Journal of the Chinese Medical Association, 2017, 80, 125-132.	0.6	24
36	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. European Radiology, 2017, 27, 2600-2609.	2.3	13

#	Article	IF	CITATIONS
37	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. Gastroenterology Research and Practice, 2017, 2017, 1-12.	0.7	14
38	Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China. Hepatology, 2016, 64, 1008-1009.	3.6	4
39	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Annals of Surgical Oncology, 2016, 23, 874-883.	0.7	51
40	Lipopolysaccharide enhanced renal vascular response to endothelinâ€1 through <scp>ET<sub>A</sub></scp> overexpression in portal hypertensive rats. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 199-207.	1.4	11
41	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. PLoS ONE, 2015, 10, e0120443.	1.1	105
42	Prognosis of Early-Stage Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e1929.	0.4	32
43	Healthy Chinese with benign pancreatic hyperenzymemia. Journal of the Chinese Medical Association, 2015, 78, 623-626.	0.6	4
44	Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation. Biomaterials, 2015, 44, 71-81.	5.7	193
45	Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology, 2015, 61, 1870-1879.	3.6	63
46	Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterology, 2015, 15, 22.	0.8	69
47	Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. Annals of Surgical Oncology, 2015, 22, 2253-2261.	0.7	31
48	ENU mutagenesis identifies mice modeling Warburg Micro Syndrome with sensory axon degeneration caused by a deletion in Rab18. Experimental Neurology, 2015, 267, 143-151.	2.0	12
49	Baculovirus-Mediated miRNA Regulation to Suppress Hepatocellular Carcinoma Tumorigenicity and Metastasis. Molecular Therapy, 2015, 23, 79-88.	3.7	30
50	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Annals of Hepatology, 2015, 14, 181-9.	0.6	12
51	Application of serologic assays for diagnosing acute hepatitis E in national surveillance of a nonendemic area. Journal of Medical Virology, 2014, 86, 720-728.	2.5	28
52	Collapsed Jugular Vein and abnormal cerebral blood flow changes in patients of Panic Disorder. Journal of Psychiatric Research, 2014, 58, 155-160.	1.5	9
53	Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study. Gastroenterology, 2014, 147, 143-151.e5.	0.6	267
54	A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child–Pugh Scores of 5 or 6. Medicine (United States), 2014, 93, e348.	0.4	17

#	Article	lF	CITATIONS
55	Antitumor activity of acriflavine in human hepatocellular carcinoma cells. Anticancer Research, 2014, 34, 3549-56.	0.5	12
56	Milan Criteria, Multi-nodularity, and Microvascular Invasion Predict the Recurrence Patterns of Hepatocellular Carcinoma After Resection. Journal of Gastrointestinal Surgery, 2013, 17, 702-711.	0.9	28
57	Chronological changes in renal vascular reactivity in portal hypertensive rats. European Journal of Clinical Investigation, 2013, 43, 267-276.	1.7	2
58	Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan. Liver International, 2013, 33, 616-623.	1.9	15
59	Differential roles of serum hepatitis <scp>B</scp> virus <scp>DNA</scp> and hepatitis <scp>B</scp> surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1849-1858.	1.4	10
60	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. International Journal of Cancer, 2013, 133, 2895-2902.	2.3	49
61	Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC. BMC Genomics, 2013, 14, 736.	1.2	45
62	Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. PLoS ONE, 2013, 8, e72049.	1.1	76
63	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology, 2013, 12, 263-273.	0.6	18
64	The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS ONE, 2013, 8, e66457.	1.1	67
65	The Effect of Age on the Long-term Prognosis of Patients With Hepatocellular Carcinoma After Resection Surgery. Archives of Surgery, 2012, 147, 137.	2.3	60
66	Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2012, 46, 789-795.	1.1	19
67	Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy. Journal of Clinical Gastroenterology, 2012, 46, 62-70.	1.1	56
68	Hepatic resection can provide long-term survival of patients with non–early-stage hepatocellular carcinoma: Extending the Indication for resection?. Surgery, 2012, 152, 809-820.	1.0	90
69	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatology International, 2012, 6, 753-762.	1.9	20
70	Hepatitis D Virus Isolates with Low Replication and Epithelial-Mesenchymal Transition-Inducing Activity Are Associated with Disease Remission. Journal of Virology, 2012, 86, 9044-9054.	1.5	11
71	MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. Journal of Clinical Investigation, 2012, 122, 2884-2897.	3.9	726
72	Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas. Clinical Gastroenterology and Hepatology, 2011, 9, 79-86.	2.4	151

#	Article	IF	CITATIONS
73	Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy. European Journal of Gastroenterology and Hepatology, 2011, 23, 1.	0.8	53
74	A Comparison of Prognosis between Patients with Hepatitis B and C Virusâ€related Hepatocellular Carcinoma Undergoing Resection Surgery. World Journal of Surgery, 2011, 35, 858-867.	0.8	87
75	Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatology International, 2010, 4, 691-699.	1.9	60
76	Pro-205 of large hepatitis delta antigen and Pro-62 of major hepatitis B surface antigen influence the assembly of different genotypes of hepatitis D virus. Journal of General Virology, 2010, 91, 1004-1012.	1.3	13
77	Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology, 2009, 50, 1464-1474.	3.6	321
78	Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification. Journal of Hepatology, 2009, 50, 779-788.	1.8	4
79	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. Journal of Hepatology, 2009, 51, 890-897.	1.8	369
80	Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2009, 43, 876-883.	1.1	25
81	Hepatitis B Surface Antigen Levels and Sequences of Natural Hepatitis B Virus Variants Influence the Assembly and Secretion of Hepatitis D Virus. Journal of Virology, 2008, 82, 2250-2264.	1.5	55
82	The Model for End-Stage Liver Disease Based Cancer Staging Systems Are Better Prognostic Models for Hepatocellular Carcinoma: A Prospective Sequential Survey. American Journal of Gastroenterology, 2007, 102, 1920-1930.	0.2	65
83	Analysis of Humoral Immunity of Hepatitis D Virus DNA Vaccine Generated in Mice by Using Different Dosage, Gene Gun Immunization, and In Vivo Electroporation. Journal of the Chinese Medical Association, 2006, 69, 7-13.	0.6	11
84	Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients. Gastroenterology, 2006, 130, 1625-1635.	0.6	193
85	The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer, 2006, 107, 141-148.	2.0	54
86	Proposal of a Modified Cancer of the Liver Italian Program Staging System Based on the Model for End-Stage Liver Disease for Patients with Hepatocellular Carcinoma Undergoing Loco-Regional Therapy. American Journal of Gastroenterology, 2006, 101, 975-982.	0.2	47
87	Diagnosis of Hepatitis D Virus Infection. , 2006, , 81-92.		1
88	Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver International, 2005, 25, 236-241.	1.9	63
89	Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 765-771.	1.4	53
90	"Defective―mutations of hepatitis D viruses in chronic hepatitis D patients. World Journal of Gastroenterology, 2005, 11, 1658.	1.4	7

#	Article	IF	Citations
91	Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. Journal of General Virology, 2004, 85, 3089-3098.	1.3	57
92	Interaction and Replication Activation of Genotype I and II Hepatitis Delta Antigens. Journal of Virology, 2004, 78, 2693-2700.	1.5	11
93	Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B?. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 841-843.	1.4	0
94	The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver International, 2004, 24, 419-424.	1.9	25
95	Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. Journal of Medical Virology, 2004, 72, 41-45.	2.5	29
96	Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. Journal of Medical Virology, 2003, 70, 74-80.	2.5	42
97	VariedImmunity Generated in Mice by DNA Vaccines with Large and SmallHepatitis DeltaAntigens. Journal of Virology, 2003, 77, 12980-12985.	1.5	23
98	Spread of hepatitis E virus among different-aged pigs: two-year survey in Taiwan. Journal of Medical Virology, 2002, 66, 488-492.	2.5	106
99	Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 1187-1191.	1.4	13
100	Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications. Hepatology, 2002, 35, 665-672.	3.6	82
101	Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: A report of two cases. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 481-483.	1.4	12
102	Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. Journal of Medical Virology, 2001, 65, 505-509.	2.5	37
103	Hereditary hemorrhagic telangiectasia: Demonstration of portosystemic venous shunts using power Doppler sonography and sonographically guided percutaneous transhepatic portovenography. Journal of Clinical Ultrasound, 2001, 29, 517-522.	0.4	6
104	Kidney transplantation in patients with chronic hepatitis B virus infection: is the prognosis worse?. Digestive Diseases and Sciences, 2001, 46, 469-475.	1,1	16
105	Clinical and epidemiological implications of swine hepatitis E virus infection. Journal of Medical Virology, 2000, 60, 166-171.	2.5	83
106	Prevalence and risk factor analysis of TTV infection in prostitutes., 2000, 60, 393-395.		11
107	Immunohistochemical Differentiation of Hepatitis D Virus Genotypes. Hepatology, 2000, 32, 1111-1116.	3.6	28
108	DNA-based immunization produces Th1 immune responses to hepatitis delta virus in a mouse model. Hepatology, 2000, 32, 104-110.	3.6	33

#	Article	IF	CITATIONS
109	Diagnostic Value of Immunoglobulin G (IgG) and IgM Anti-Hepatitis E Virus (HEV) Tests Based on HEV RNA in an Area Where Hepatitis E Is Not Endemic. Journal of Clinical Microbiology, 2000, 38, 3915-3918.	1.8	70
110	Prospective Case-controlled Trial of Adjuvant Chemotherapy after Resection of Hepatocellular Carcinoma. World Journal of Surgery, 2000, 24, 551-555.	0.8	39
111	Mixed genotypes infection with hepatitis D virus. Journal of Medical Virology, 1999, 57, 64-67.	2.5	34
112	Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 1999, 11, 315-322.	0.8	46
113	Diagnostic value of antiâ€hepatitis D virus (HDV) antibodies revisited: A study of total and IgM antiâ€HDV compared with detection of HDVâ€RNA by polymerase chain reaction. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 57-61.	1.4	19
114	Clinical significance of serum autoâ€antibodies in Chinese patients with chronic hepatitis C: Negative role of serum viral titre and genotype. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 475-479.	1.4	32
115	The impact of traveling to endemic areas on the spread of hepatitis E virus infection: Epidemiological and molecular analyses. Hepatology, 1998, 27, 1415-1420.	3.6	50
116	Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology, 1998, 28, 231-236.	3.6	233
117	Prevalence, implication, and viral nucleotide sequence analysis of GB virus-C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis., 1998, 56, 118-122.		12
118	Detection of serum hepatitis B, C, and D viral nucleic acids and its implications in hepatocellular carcinoma patients. Journal of Gastroenterology, 1998, 33, 512-516.	2.3	18
119	Analysis of T cell receptor $\hat{V^2}$ gene usage during the course of disease in patients with chronic hepatitis B. Journal of Biomedical Science, 1998, 5, 428-434.	2.6	5
120	A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 87-91.	1.4	68
121	Decreasing hepatitis D virus infection in Taiwan: An analysis of contributory factors. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 747-751.	1.4	72
122	Prevalence and risk factor analysis of GBV-C/HGV infection in prostitutes. Journal of Medical Virology, 1997, 52, 83-85.	2.5	38
123	Prevalence and risk factor analysis of GBV /HGV infection in prostitutes. Journal of Medical Virology, 1997, 52, 83-85.	2.5	3
124	Prevalence and Type of Precore Hepatitis B Virus Mutants in Hepatitis D Virus Superinfection and Its Clinical Implications. Journal of Infectious Diseases, 1996, 173, 457-459.	1.9	13
125	Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 237-240.	1.4	22
126	Injection with nondisposable needles as an important route for transmission of acute community-acquired hepatitis C virus infection in Taiwan. Journal of Medical Virology, 1995, 46, 247-251.	2.5	48

#	Article	IF	Citations
127	Evidence of transmission of hepatitis D virus to spouses from sequence analysis of the viral genome. Hepatology, 1995, 22, 1656-1660.	3.6	54
128	Natural history of hepatitis D viral superinfection: Significance of viremia detected by polymerase chain reaction. Gastroenterology, 1995, 108, 796-802.	0.6	143
129	Factors associated with viremia and elevated transaminase levels in asymptomatic hepatitis D virus-infected risk groups. Journal of Medical Virology, 1994, 42, 86-90.	2.5	11
130	Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: Application and limitations of the polymerase chain reaction. Hepatology, 1994, 19, 836-840.	3.6	124
131	Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: Application and limitations of the polymerase chain reaction. Hepatology, 1994, 19, 836-840.	3.6	20
132	Prevalence, infectivity, and risk factor analysis of hepatitis C virus infection in prostitutes. Journal of Medical Virology, 1993, 39, 312-317.	2.5	55
133	Hepatitis D virus infection among prostitutes in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 334-337.	1.4	21
134	Prevalence of anti-HCV among Chinese patients with acute and chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 113-116.	1.4	8
135	Expression and localization of the small and large delta antigens during the replication cycle of hepatitis D virus. Hepatology, 1992, 16, 1120-1127.	3.6	32
136	The prevalence of anti-hepatitis C virus among chinese patients with hepatocellular carcinoma. Cancer, 1992, 69, 342-345.	2.0	64
137	Expression and localization of the small and large delta antigens during the replication cycle of hepatitis D virus. Hepatology, 1992, 16, 1120-1127.	3.6	5
138	Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B. Scandinavian Journal of Infectious Diseases, 1991, 23, 421-424.	1.5	27
139	Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology, 1991, 13, 830-833.	3.6	104
140	A prospective study of post-transfusion non-A, non-B (type C) hepatitis following cardiovascular surgery in Taiwan. Journal of Medical Virology, 1991, 33, 188-192.	2.5	26
141	Acute hepatitis B viral infection in a patient with anti-HBs. Journal of Medical Virology, 1991, 35, 133-135.	2.5	7
142	Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology, 1991, 13, 830-833.	3.6	14
143	Sexual transmission of hepatitis D virus infection in Taiwan. Hepatology, 1990, 11, 1057-1061.	3.6	40
144	HBsAg carrier infants with serum anti-HBc negativity. Hepatology, 1989, 9, 102-104.	3.6	41

#	Article	IF	CITATIONS
145	Utility of sono-graphic gallbladder wall patterns in differentiating malignant from cirrhotic ascites. Journal of Clinical Ultrasound, 1989, 17, 187-192.	0.4	10
146	Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemotherapy and Pharmacology, 1989, 23, 54-6.	1.1	26
147	Symptomatic anti-HBe positive chronic hepatitis B in taiwan with special reference to persistent HBV replication and HDV superinfection. Journal of Medical Virology, 1988, 25, 141-148.	2.5	19
148	Mass screening of primary hepatocellular carcinoma by alphaâ€fetoprotein in a rural area of Taiwan – a dried blood spot method. Liver, 1988, 8, 100-104.	0.1	20
149	Natural and activated cytotoxic lymphocytes reactivity to human hepatocellular carcinoma cell lines in hepatocellular carcinoma patients. Liver, 1988, 8, 198-207.	0.1	7
150	Hepatitis D Virus (Delta Agent) Superinfection in an Endemic Area of Hepatitis B Infection: Immunopathologic and Serologic Findings. Scandinavian Journal of Infectious Diseases, 1987, 19, 173-177.	1.5	18
151	Prevention of maternal-infant hepatitis B virus transmission by immunization: The role of serum hepatitis B virus DNA. Hepatology, 1986, 6, 369-373.	3.6	110
152	Hepatitis B and D Virus Infection Among Drug Abusers in Taiwan. Journal of Medical Virology, 1986, 20, 247-252.	2.5	38